Nordic Science Investments leads GlobeVAC’s €450K pre-seed round
GlobeVAC, a University of Helsinki spin-out focused on vaccine and biologics stabilisation, has raised €450,000 in a pre-seed funding round led by Nordic Science Investments (NSI), with participation from the University of Helsinki and Moonstone Venture Capital.
The company is addressing one of the most critical and overlooked challenges in global healthcare—the cold chain, which requires vaccines and biologics to be stored and transported at low temperatures. This infrastructure significantly increases costs and limits access, particularly in low- and middle-income countries.
GlobeVAC has developed a platform that stabilises vaccines and biologics at room and elevated temperatures for months, using sustainable, cellulose-based biopolymers derived from wood industry waste. The technology has been preclinically validated across multiple modalities, including viral and mRNA vaccines, live attenuated vaccines, antibodies, and bacteria, with stability demonstrated for up to 6–8 months.
The company builds on years of research from Professor Vincenzo Cerullo at the University of Helsinki’s ImmunoViroTherapy Lab and is led by CEO Manlio Fusciello and CTO Paolo Bottega. The team is now working to translate academic breakthroughs into industrial partnerships with global vaccine and biologics manufacturers.
Manlio Fusciello, CEO and Co-founder of GlobeVAC, said: “Launching GlobeVAC is both a milestone and a responsibility. Our technology has the potential to reshape how vaccines and biologics are produced, stored, and delivered, cutting costs for manufacturers and expanding access for patients, in both human and animal health.”
Professor Vincenzo Cerullo, Scientific Founder of GlobeVAC, added: “Seeing years of rigorous science move from the laboratory into a company with real-world impact is always a privilege. GlobeVAC represents the best of translational research, combining scientific excellence with the ambition to make medicines more accessible to people worldwide.”
The funding will support GlobeVAC’s transition from academic validation to commercialisation, enabling the company to scale its platform and engage with partners across the global pharma and biotech ecosystem.
This private round follows earlier non-dilutive funding, including €1.25 million from Business Finland’s Research to Business programme and a €150,000 European Research Council (ERC) Proof of Concept grant, bringing total funding committed to the technology to approximately €1.85 million.
Nordic Science Investments highlighted the company’s strong scientific foundation and clear path from lab to industry, backing GlobeVAC at inception to support its mission of expanding access to life-saving medicines globally.
Newer
There are no newer news
